Form 8-K - Current report:
SEC Accession No. 0001737287-20-000041
Filing Date
2020-06-11
Accepted
2020-06-10 18:17:35
Documents
14
Period of Report
2020-06-05
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K allo-20200605.htm   iXBRL 8-K 58026
  Complete submission text file 0001737287-20-000041.txt   202278

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20200605.xsd EX-101.SCH 2649
3 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT allo-20200605_cal.xml EX-101.CAL 795
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20200605_def.xml EX-101.DEF 1759
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20200605_lab.xml EX-101.LAB 24270
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20200605_pre.xml EX-101.PRE 12731
15 EXTRACTED XBRL INSTANCE DOCUMENT allo-20200605_htm.xml XML 10789
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 20955711
SIC: 2836 Biological Products, (No Diagnostic Substances)